2 Information about dabrafenib with trametinib

Information about dabrafenib with trametinib

Anticipated marketing

Dabrafenib (Tafinlar, Novartis Pharmaceuticals) with trametinib (Mekinist, Novartis Pharmaceuticals) is indicated for 'the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection'.

Dosage in the marketing authorisation

For dabrafenib, the recommended dose is 150 mg taken orally, twice daily. For trametinib, the recommended dose is 2 mg taken orally, once daily.


The list price for 28 capsules of dabrafenib 75 mg is £1,400 and for 30 tablets of trametinib 2 mg is £4,800 (company submission).

The company has a commercial arrangement for each drug. This makes dabrafenib with trametinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)